InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register account icon
S&P 500
5,505.00
(
-0.71%
)
US TECH 100
19,000.00
(
-0.94%
)
Dow Jones
40,287.53
(
-0.93%
)
Brent Oil
82.18
(
-0.13%
)
Bitcoin
67,234.27
(
-1.35%
)
Post# of 252642
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 831
Posts 120081
Boards Moderated 16
Alias Born 09/05/2002

DewDiligence

Member Level

Re: Whalatane post# 240045

Tuesday, 10/19/2021 7:37:16 PM

Tuesday, October 19, 2021 7:37:16 PM

Post# of 252642
AVIR—If an antiviral drug can't reduce viral load better than placebo, you have a problem, but CEO Jean-Pierre Sommadossi actually said on today's CC that the clinical results were "as expected."

AVIR is already dosing AT-527 at a whopping 2200mg/day (1100mg BID), and the FDA won't let AVIR go higher because of toxicity with a chemically similar HCV drug that BMY discontinued in 2012 (#msg-78868766). I see no possible path for the AT-527 program to be resuscitated.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up